Celltrion gains EC approval for Avtozma, a RoActemra biosimilar for autoimmune diseases
Celltrion has received marketing authorization from the European Commission (EC) for Avtozma, a biosimilar to RoActemra (tocilizumab), expanding the company’s footprint in the immunology and ... Read More
Gloriosa Superba: Chemical constituents, medicinal uses, and pharmaceutical importance
Gloriosa superba, commonly referred to as the glory lily, is a highly valued medicinal plant recognized for its potent chemical composition and extensive pharmaceutical applications. ... Read More
Bio-Thera Solutions and Tabuk Pharmaceuticals partner to bring BAT2206 to Saudi Arabia
Bio-Thera Solutions Inc., a Chinese biopharmaceutical company, has announced a strategic partnership with Tabuk Pharmaceutical Manufacturing Company, a leading player in the Middle East and ... Read More
AbbVie to expand immunology pipeline with Nimble Therapeutics acquisition
In a significant move to solidify its presence in immunology, AbbVie has announced the acquisition of Nimble Therapeutics, a company at the forefront of peptide-based ... Read More
AstraZeneca to acquire Gracell Biotechnologies for $1.2bn to expand cell therapy capabilities
AstraZeneca has announced a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL) for an upfront cash payment of $1.0 billion, representing a 62% ... Read More
Immutep taps Charles River for IMP761 LAG-3 antibody preclinical study
Immutep Limited, an Australian biotech company specializing in LAG-3 immunotherapies for cancer and autoimmune diseases, has partnered with Charles River Laboratories to conduct a GLP ... Read More
Gilead Sciences partners with EVOQ Therapeutics on immunotherapies
American biopharma major Gilead Sciences and immunotherapy company EVOQ Therapeutics have entered into a partnership to develop and market immunotherapy products. Under the collaboration and ... Read More
Amgen to acquire American biopharma company ChemoCentryx for $3.7bn
Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases and cancer, in an all-cash deal worth ... Read More
French biotech company Step Pharma raises €35m in a Series B round
Step Pharma has raised €35 million in a Series B financing round for advancing STP938, its lead CTPS1 inhibitor into clinical development for the treatment ... Read More
Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators
Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma for the research, development, and commercialization of ... Read More